Abstract PS4-10: Serial MRI and pathology combined to select candidates for therapy de-escalation in the I-SPY 2 TRIAL
Sara J. Venters(University of California, San Francisco), Nola M. Hylton(University of California, San Francisco), Denise M. Wolf, Jodi M. Carter(University of Alberta), Kimmie Rabe(University of Minnesota), Sonal Shad(University of California, San Francisco), Laura van ‘t Veer, Barbara LeStage(City College of San Francisco), Lamorna Brown Swigart(University of California, San Francisco), Jessica Gibbs(City College of San Francisco), Natsuko Onishi(City College of San Francisco), Kamaljeet Singh, Laila Khazai(Moffitt Cancer Center), Sunati Sahoo(The University of Texas Southwestern Medical Center), Yunn‐Yi Chen(University of Vermont), Shuko Harada(University of Alabama at Birmingham), Amy L. Delson(Children's Advocacy Center), Malini Harigopal, Christina Yau(Hospital Authority), Alexander D. Borowsky(University of California, San Francisco), Ronald Balassanian, Laura Esserman(UCSF Helen Diller Family Comprehensive Cancer Center), Wen Li(Michigan State University), Gregor Krings(Cleveland Clinic), Molly Klein(University of Minnesota), Kimberley Cole(Yale University), I Tolgay Ocal, W. Fraser Symmans(The University of Texas MD Anderson Cancer Center), David Newitt(City College of San Francisco), Sandra A. Finestone(Consumers Union)
Cited by 1
Related Papers
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
|New England Journal of Medicine|2002|6.5k
The Immune Landscape of Cancer
|Immunity|2018|6.3k
An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics
|Cell|2018|4k